T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity

SIMPLE SUMMARY: The development of effective adoptive T-cell therapies (ATCs) to treat solid tumors has several challenges: the choice of a suitable target antigen, the generation of a specific T-cell receptor (TCR) directed against this target, and the hostile tumor microenvironment (TME). The canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sailer, Nadja, Fetzer, Ina, Salvermoser, Melanie, Braun, Monika, Brechtefeld, Doris, Krendl, Christian, Geiger, Christiane, Mutze, Kathrin, Noessner, Elfriede, Schendel, Dolores J., Bürdek, Maja, Wilde, Susanne, Sommermeyer, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030144/
https://www.ncbi.nlm.nih.gov/pubmed/35454906
http://dx.doi.org/10.3390/cancers14081998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030144/
https://www.ncbi.nlm.nih.gov/pubmed/35454906
http://dx.doi.org/10.3390/cancers14081998

Ejemplares similares